AI Article Synopsis
- - Oligometastatic disease in squamous cell carcinoma of the head and neck (HNSCC) involves a low burden of metastatic disease that may still be treated curatively, despite common complications like loco-regional recurrences.
- - The study uses various sources, including PubMed and clinical trials databases, to gather evidence on how to treat oligometastatic HNSCC patients, particularly focusing on metastasis-directed therapies such as stereotactic ablative radiotherapy (SABR).
- - The findings emphasize the importance of a multidisciplinary approach for managing oligometastatic HNSCC, as this collaboration appears crucial in optimizing patient outcomes.
Article Abstract
Introduction: The oligometastatic disease is a low burden metastatic disease that might still benefit from curable treatment. Squamous cell carcinoma of the head and neck (HNSCC) is a complex group of malignancies, with high rates of loco-regional recurrences. Distant metastases are less frequent, and a single or few deposits are often observed (oligometastatic disease). The optimal management of oligometastatic HNSCC remains to be defined.
Materials And Methods: Key references were derived from a PubMed query. Hand searching and clinicaltrials.gov were also used.
Results: This paper contains a narrative report and a critical discussion of the available evidence on the management of oligometastatic HNSCC patients, with a focus on metastasis-directed therapy (MDT), particularly stereotactic ablative radiotherapy (SABR).
Conclusions: in line with literature data, the multidisciplinary evaluation emerged as the key element in the management of oligometastatic HNSCC patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.critrevonc.2023.103968 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!